PI-3K inhibitors exert a preferential effect on CD15+ TPCs isolated from Smo A1Tg model of medulloblastoma and in human patient derived xenografts, with minimal to no effect on CD15- population. This evidence concerns the gene FUT4 and medulloblastoma.